Abstract
KIT exon 17 mutation is a poor prognostic factor in core-binding factor acute myeloid leukemia. However, the mutation detection method used for risk assessment is not assigned. It is necessary to verify the analytical and clinical performance before applying new methods. Herein, we firstly applied a highly sensitive allele-specific, real-time quantitative PCR (AS-qPCR) assay to analyze KIT mutations, which demonstrated excellent sensitivity and specificity. Much higher incidence of KIT mutations (62.2%, 69/111) and prevalence of multiple mutations (43.5%, 30/69) were observed using AS-qPCR, which meant the existence of multiple KIT mutant subclones. The relative KIT mutant level was variable (median, 0.3 per control allele 100 copies, 0.002-532.7) and was divided into two groups: high (⩾10, n=26) and low (<10) mutant level. Interestingly, rather than mutation positivity, mutant level was found to be associated with clinical outcome. High mutant level showed significantly inferior overall survival (P=0.005) and event-free survival (P=0.03), whereas low level did not influence the prognosis. The follow-up data showed that the mutant level were along with fusion transcripts in the majority (n=29), but moved separately in some case...Continue Reading
References
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Apr 11, 1989·Nucleic Acids Research·C R NewtonA F Markham
Jan 3, 2001·Blood·S MeshinchiJ P Radich
Sep 19, 2001·Current Opinion in Hematology·D G Gilliland
Sep 21, 2001·Current Opinion in Hematology
Sep 20, 2002·Blood·Lee-Yung ShihHui-Chin Hsu
Jan 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yue-Ying WangSai-Juan Chen
Dec 31, 2005·Blood·Roberto CairoliEnrica Morra
Apr 7, 2006·Leukemia·N BoisselUNKNOWN Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Mar 21, 2007·Blood·Seoyeon ChoiMurray D Norris
Oct 26, 2007·Leukemia·L-Y ShihT-C Yeh
Apr 4, 2008·Leukemia·H BeckerM Lübbert
Jan 9, 2010·Blood·Jessica A PollardSoheil Meshinchi
May 25, 2011·Leukemia·S WakitaK Inokuchi
Jul 1, 2011·Leukemia Research·Sang Hyuk ParkChan-Jeoung Park
Oct 8, 2011·The Journal of Molecular Diagnostics : JMD·Seung-Tae LeeChang-Seok Ki
Oct 12, 2012·Annals of Hematology·Hee-Jin KimUNKNOWN L/MDS working party, Korean Society of Hematology
Oct 13, 2012·British Journal of Haematology·Anthony J BenchUNKNOWN British Committee for Standards in Haematology
Nov 7, 2012·Expert Opinion on Investigational Drugs·Leonie K Ashman, Renate Griffith
Dec 5, 2012·Bone Marrow Transplantation·Y Kanda
Mar 8, 2013·Oncology Reports·Ludovica RieraAchille Pich
Jun 21, 2013·Leukemia·C AllenR E Gale
Jun 25, 2014·Oncology Letters·Quanyi LuXiaomin Zhao
Aug 2, 2014·Blood·Yu WangXiao-Jun Huang
Aug 12, 2014·Bone Marrow Transplantation·J-H YoonC-W Park
Dec 3, 2014·Leukemia Research·Ya-Zhen QinXiao-Jun Huang
Citations
Feb 15, 2019·Laboratory Investigation; a Journal of Technical Methods and Pathology·Richard J KarpowiczVirginia M-Y Lee
Aug 26, 2016·HLA : Immune Response Genetics·Z LiuH Wang
Aug 9, 2018·Blood Cancer Journal·Ya-Zhen QinXiao-Jun Huang
Nov 7, 2019·Journal of Pediatric Hematology/oncology·Jae Wook LeeMyungshin Kim
Jun 30, 2021·Bone Marrow Transplantation·Byung-Sik ChoHee-Je Kim
Nov 6, 2021·International Journal of Hematology·Akio MoriTakeshi Kondo